Back to top
more

Lexicon Pharmaceuticals (LXRX)

(Delayed Data from NSDQ)

$1.27 USD

1.27
2,935,556

-0.03 (-2.31%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $1.26 -0.01 (-0.79%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Viatris Beats on Q3 Earnings and Revenues, Lowers Profit Guidance

by Zacks Equity Research

VTRS Q3 earnings and sales beat estimates. New products perform well.

Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 5.56% and 2.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More

by Ekta Bagri

Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.

Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista

by Zacks Equity Research

The FDA plans to hold an Advisory Committee meeting to give a recommendation for Lexicon's (LXRX) Zynquista (sotagliflozin) on Oct 31, 2024. Stock up.

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up

by Zacks Equity Research

Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 5.56% and 39.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

by Ekta Bagri

Cassava Sciences, Inc. (SAVA) and Lexeo Therapeutics (LXEO) are in the spotlight following updates.

FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug

by Zacks Equity Research

The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength?

by Zacks Equity Research

IDEAYA Biosciences (IDYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Nalak Das headshot

Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio

by Nalak Das

We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.

Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?

by Zacks Equity Research

Tango Therapeutics (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of -11.11% and 3.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy

by Zacks Equity Research

Lexicon (LXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

by Zacks Equity Research

New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of 13.04% and 3.24%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 89.47% and 7.55%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 1.07% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts

by Zacks Equity Research

A pharmacy benefit manager decides to place Lexicon's (LXRX) heart failure drug as a preferred product on Medicare national formularies on Nov. 1. The stock jumped 12% post this announcement.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lexicon (LXRX) delivered earnings and revenue surprises of -29.41% and 5.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector.

Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval

by Zacks Equity Research

Lexicon's (LXRX) shares rise as it receives FDA approval for Inpefa, a once-daily oral tablet to treat a broad population of heart failure patients.

The Zacks Analyst Blog Highlights Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals

by Zacks Equity Research

Moderna, Gilead Sciences, Kodiak Sciences and Lexicon Pharmaceuticals have been highlighted in this Analyst Blog.

Biotech Stock Roundup: MRNA's Q4 Earnings, LXRX, KOD Down on Updates & More

by Zacks Equity Research

Updates from Moderna (MRNA) and Kodiak Sciences Inc (KOD) are a few key highlights from the biotech sector during the past week.

Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug

by Zacks Equity Research

Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.